IBA Signs Contract with Partner CGN Medical Technology for the Installation of a Proteus PLUS System in China

August 15, 2023 — IBA, a world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announced it has signed an equipment contract with its partner CGN Medical Technology (CGNMT) for IBA’s Proteus PLUS[1] proton therapy system, with one gantry treatment room to be installed at the West China International Cancer Treatment Center in Chengdu, Sichuan Province. 

CGNMT is the sole proton therapy system vendor for West China International Cancer Treatment Center in Chengdu. Following the strategic licensing agreement signed between IBA and CGNNT in 2020, IBA provides the key components of the Proteus PLUS system to CGNMT which will be installed at the hospital site. CGNMT will be responsible for the installation, commissioning, service and maintenance of the proton therapy equipment. 

Olivier Legrain, Chief Executive Officer of IBA, commented: "This project is the ninth Proteus PLUS system to be installed in China and the second order received from CGNMT since the beginning of our successful collaboration. We were happy to meet the management team of CGNMT in person for the first time since the pandemic and the signature of our agreement. We have been impressed with the progress that has been made so far by our partner and look forward to continuing our relationship with them to ensure the future success and expansion of proton therapy in the Chinese market." 

HU Dongming, Chairman of CGN Nuclear Technology Development Co., Ltd., added: "We were happy to welcome Mr. Legrain and his team to CGN in Shenzhen and celebrate the fantastic progress we have made in the delivery of this innovative technology to the Chinese market. We are pleased and honored to be working with the West China International Cancer Treatment Center which demonstrates the potential of our collaboration for the benefit of cancer patients in China. We look forward to strengthening our relationship with IBA as we continue with this project." 

For more information: www.iba-worldwide.com